SCM
INDV icon

Scopia Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Scopia Capital Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,654,855
Closed -$24.4M – 36
2025
Q2 		$24.4M Sell
1,654,855
-220,253
-12% -$2.57M 2.98% 16
2025
Q1 		$17.9M Buy
1,875,108
+391,984
+26% +$4.12M 2.59% 19
2024
Q4 		$18.4M Buy
1,483,124
+199,038
+16% +$2.05M 1.95% 19
2024
Q3 		$12.5M Sell
1,284,086
-4,617,156
-78% -$54.1M 2.58% 22
2024
Q2 		$92.5M Sell
5,901,242
-123,991
-2% -$2.24M 13.7% 1
2024
Q1 		$129M Sell
6,025,233
-2,236,356
-27% -$42M 14.12% 1
2023
Q4 		$126M Sell
8,261,589
-49,778
-0.6% -$884K 15.6% 1
2023
Q3 		$192M Sell
8,311,367
-1,279,554
-13% -$29.2M 23.68% 1
2023
Q2 		$228M Buy
+9,590,921
New +$220M 23.07% 1

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $4.41B AUM 90.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Scopia Capital Management's INDV Position: Q3 2025 in Review

Scopia Capital Management sold out of Indivior Pharmaceuticals (INDV) in Q3 2025, closing a stake of 1,654,855 shares — an estimated $24.4M sold.

Scopia Capital Management first reported a position in INDV in Q2 2023 and held it in 9 quarters. The position peaked at $228M in Q2 2023. 198 funds tracked by Wall St. Rank hold INDV as of Q3 2025.

  • Scopia Capital Management reported no remaining Indivior Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Scopia Capital Management sold 1,654,855 Indivior Pharmaceuticals shares in Q3 2025, an estimated $24.4M.
  • Scopia Capital Management first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 9 quarters.
  • Scopia Capital Management's Indivior Pharmaceuticals position peaked at $228M in Q2 2023.
  • 198 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2025.

Based on Scopia Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.